Tailoring drug and gene codelivery nanosystems for glioblastoma treatment
Glioblastoma is the most common primary and aggressive brain tumour, with an increasing incidence worldwide. The prognosis of this disease is still poor, with a median survival time not exceeding two years. Standard-of-care therapy includes surgical resection, radio- and chemotherapy, but nearly all...
| Autor principal: | |
|---|---|
| Outros Autores: | , , , , |
| Formato: | bookPart |
| Idioma: | eng |
| Publicado em: |
2020
|
| Assuntos: | |
| Texto completo: | http://hdl.handle.net/10316/90781 |
| País: | Portugal |
| Oai: | oai:estudogeral.sib.uc.pt:10316/90781 |